<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Endocr Disord</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Endocr Disord</journal-id>
      <journal-title-group>
        <journal-title>BMC Endocrine Disorders</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1472-6823</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27881164</article-id>
      <article-id pub-id-type="pmc">5122017</article-id>
      <article-id pub-id-type="publisher-id">148</article-id>
      <article-id pub-id-type="doi">10.1186/s12902-016-0148-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Takeno</surname>
            <given-names>Ayumu</given-names>
          </name>
          <address>
            <phone>+81-853-20-2183</phone>
            <email>atakeno@med.shimane-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Masahiro</given-names>
          </name>
          <address>
            <email>masa-ya@med.shimane-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Notsu</surname>
            <given-names>Masakazu</given-names>
          </name>
          <address>
            <email>mnotsu25@med.shimane-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sugimoto</surname>
            <given-names>Toshitsugu</given-names>
          </name>
          <address>
            <email>sugimoto@med.shimane-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, Izumo, Shimane 693-8501 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>16</volume>
      <elocation-id>66</elocation-id>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Growth hormone deficiency (GHD) is associated with non-alcoholic fatty liver disease (NAFLD). A recent animal study showed that hepatocyte-specific receptor activator of nuclear factor-kappa B (RANK) knockout mice had significantly lower liver fat content compared with control mice concomitant with a decrease in production of inflammatory cytokines such as tumor necrosis factor-&#x3B1; (TNF-&#x3B1;) from hepatocytes and kupffer cells. The role of anti-RANK ligand (RANKL) antibody for osteoporosis on hepatitis in patients with aGHD is still unknown.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A forty-seven-year-old female patient was referred to our hospital to investigate chronic hepatitis caused by unknown etiology. She had past history of craniopharyngioma treated with craniotomy and post-surgical radiotherapy. She was for the first time diagnosed as panhypopituitarism including growth hormone deficiency and osteoporosis by endocrine examinations and bone mineral densitometry, respectively. In addition, non-alcoholic steatohepatitis (NASH) was histologically confirmed by liver biopsy in this time. Sixty mg anti-RANKL antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of 5&#xA0;mg hydrocortisone and 30&#xA0;&#x3BC;g oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and &#x3B3;GTP were 133 to 72 U/L and 284 to 99 U/L at 16&#xA0;months after the beginning of the treatment, respectively). Additional amelioration of liver dysfunction was not observed after growth hormone replacement.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The clinical course of the present case suggested that RANKL-RANK signaling may be a key pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism including GHD.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Growth hormone deficiency (GHD)</kwd>
        <kwd>Non-alcoholic fatty liver disease (NAFLD)</kwd>
        <kwd>Non-alcoholic steatohepatitis (NASH)</kwd>
        <kwd>Receptor activator of nuclear factor-kappa B ligand (RANKL)</kwd>
        <kwd>Denosumab</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Non-alcoholic fatty liver disease (NAFLD) defines liver abnormalities ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) with or without cirrhosis development. Prevalence of NAFLD is massively increasing because that is related to obesity [<xref ref-type="bibr" rid="CR1">1</xref>]. Recently, several clinical studies have shown that growth hormone deficiency (GHD) is complicated with NAFLD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and that growth hormone (GH) replacement therapy improves liver dysfunction [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>] and histological findings of NAFLD [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], suggesting that GHD is considered as one of the pathological causes for NAFLD. However, detailed mechanisms of establishment of NAFLD in patients with GHD are still unknown.</p>
      <p>Receptor activator of nuclear factor-kappa B ligand (RANKL) is an osteoclast differentiating factor which binds to receptor activator of nuclear factor-kappa B (RANK) on the surface of osteoclasts and enhances osteoclast differentiation, function and bone resorption [<xref ref-type="bibr" rid="CR7">7</xref>]. An anti-RANKL antibody, denosumab, is clinically used as an anti-osteoporotic agent which increases bone mineral density (BMD) by inhibiting bone resorption [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. We report the first case of adult-GHD (aGHD) that administration of anti-RANKL antibody for the treatment of osteoporosis was associated with amelioration of hepatitis.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 47-year-old debile female patient was referred to our hospital to examine hepatitis caused by unknown etiology. At 11&#xA0;years of age, she was diagnosed as craniopharyngioma and treated with craniotomy and post-surgical radiotherapy. Sex hormone replacement was performed for hypogonadotropic hypogonadism from 15 to 44&#xA0;years old. Elevated liver enzymes were observed about past 20&#xA0;years.</p>
      <p>She was an underweight woman (body height, 149.3&#xA0;cm; body weight, 36.5&#xA0;kg; BMI 16.4&#xA0;kg/m<sup>2</sup>) who had no alcohol consumption. Laboratory findings showed elevated liver enzymes (AST, ALT and &#x3B3;GTP were 131 U/L, 106 U/L and 238 U/L, respectively) concomitant with an extremely low concentration of insulin-like growth factor-1 (IGF-1) (12&#xA0;ng/mL) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Abdominal ultrasonography showed fatty liver. Hepatitis B surface antigen, anti-hepatitis C virus antibody, anti-nuclear antibody and anti-mitochondrial M2 antibody were undetectable. Histological findings of the liver biopsy were compatible with NASH (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a&#x2013;d</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Laboratory tests</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Level measured</th><th colspan="3">Reference range</th></tr></thead><tbody><tr><td colspan="6">&#x300A;Biochemical Profiles&#x300B;</td></tr><tr><td>&#x2003;AST</td><td colspan="2">131 U/L</td><td colspan="3">(10&#x2013;38)</td></tr><tr><td>&#x2003;ALT</td><td colspan="2">106 U/L</td><td colspan="3">(5&#x2013;40)</td></tr><tr><td>&#x2003;&#x3B3;GTP</td><td colspan="2">238 U/L</td><td colspan="3">(0&#x2013;75)</td></tr><tr><td>&#x2003;ALP</td><td colspan="2">439 U/L</td><td colspan="3">(21&#x2013;80)</td></tr><tr><td>&#x2003;BUN</td><td colspan="2">7.4 mg/dL</td><td colspan="3">(8.0&#x2013;21.0)</td></tr><tr><td>&#x2003;Cr</td><td colspan="2">0.53 mg/dL</td><td colspan="3">(0.44&#x2013;0.83)</td></tr><tr><td>&#x2003;Na</td><td colspan="2">145 mEq/L</td><td colspan="3">(137&#x2013;146)</td></tr><tr><td>&#x2003;K</td><td colspan="2">3.5 mEq/L</td><td colspan="3">(3.5&#x2013;4.9)</td></tr><tr><td>&#x2003;Cl</td><td colspan="2">111 mEq/L</td><td colspan="3">(98&#x2013;109)</td></tr><tr><td>&#x2003;LDL-C</td><td colspan="2">98 mg/dL</td><td colspan="3">(70&#x2013;139)</td></tr><tr><td>&#x2003;HDL-C</td><td colspan="2">38 mg/dL</td><td colspan="3">(40&#x2013;80)</td></tr><tr><td>&#x2003;TG</td><td colspan="2">106 mg/dL</td><td colspan="3">(50&#x2013;140)</td></tr><tr><td>&#x2003;HbA1c</td><td colspan="2">5.7%</td><td colspan="3">(4.7&#x2013;6.2)</td></tr><tr><td>&#x2003;FPG</td><td colspan="2">78 mg/dL</td><td colspan="3">(60&#x2013;109)</td></tr><tr><td colspan="6">&#x300A;Endocrine Profiles&#x300B;</td></tr><tr><td>&#x2003;GH</td><td colspan="2">0.1 ng/mL</td><td colspan="3">(&lt;3.0)</td></tr><tr><td>&#x2003;IGF-1</td><td colspan="2">12 ng/mL</td><td colspan="3">(83&#x2013;221)</td></tr><tr><td>&#x2003;PRL</td><td colspan="2">13.3 ng/mL</td><td colspan="3">(3.2&#x2013;26.2)</td></tr><tr><td>&#x2003;LH</td><td colspan="2">&lt;0.2 mIU/mL</td><td colspan="3">(1.13&#x2013;88.33)</td></tr><tr><td>&#x2003;FSH</td><td colspan="2">&lt;0.1 mIU/mL</td><td colspan="3">(3.01&#x2013;16.60)</td></tr><tr><td>&#x2003;E2</td><td colspan="2">&lt;7 pg/mL</td><td colspan="3">(7&#x2013;509)</td></tr><tr><td>&#x2003;TSH</td><td colspan="2">4.76 &#x3BC;U/mL</td><td colspan="3">(0.50&#x2013;3.00)</td></tr><tr><td>&#x2003;FT4</td><td colspan="2">0.6 ng/dL</td><td colspan="3">(0.8&#x2013;1.5)</td></tr><tr><td>&#x2003;FT3</td><td colspan="2">2.4 pg/mL</td><td colspan="3">(2.1&#x2013;3.8)</td></tr><tr><td>&#x2003;ACTH</td><td colspan="2">17.4 pg/mL</td><td colspan="3">(7.2&#x2013;63.3)</td></tr><tr><td>&#x2003;cortisol</td><td colspan="2">2 &#x3BC;g/dL</td><td colspan="3">(2&#x2013;18)</td></tr><tr><td>&#x2003;u-cortisol</td><td colspan="2">undetectable</td><td colspan="3">(11.2&#x2013;80.3)</td></tr><tr><td>&#x2003;ADH</td><td colspan="2">&lt;0.8 pg/mL</td><td colspan="3">(&lt;4.2)</td></tr><tr><td>&#x2003;s-Osm</td><td colspan="2">289 mOsm/L</td><td colspan="3">(270&#x2013;295)</td></tr><tr><td>&#x2003;u-Osm</td><td colspan="2">250&#xA0;L mOsm/L</td><td colspan="3">(50&#x2013;1300)</td></tr><tr><td colspan="6">GHRP-2 loading test</td></tr><tr><td>&#x2003;Time (min)</td><td>0</td><td>15</td><td>30</td><td>45</td><td>60</td></tr><tr><td>&#x2003;GH (ng/mL)</td><td>0.1</td><td>0.4</td><td>0.4</td><td>0.3</td><td>0.2</td></tr></tbody></table></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Liver biopsy samples. Hematoxylin and eosin (H&amp;E) staining showed steatosis (50%), infiltrations of inflammatory cells and hepatocyte ballooning (Fig.&#xA0;1<bold>a</bold> and <bold>b</bold>: &#xD7;100 and &#xD7;400, respectively). Azan-mallory staining showed fibrosis of portal region (Fig.&#xA0;1<bold>c</bold>: &#xD7;100), and silver staining showed pericellular fibrosis (Fig.&#xA0;1<bold>d</bold>: &#xD7;400). These findings were compatible to the diagnosis of NASH. These findings were compatible with NASH (grade 2 and stage 2)</p></caption><graphic xlink:href="12902_2016_148_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>aGHD was diagnosed by loading test with 100&#xA0;&#x3BC;g GH-releasing peptide-2 (GHRP-2) [basal level: 0.1&#xA0;ng/mL, peak level: 0.4&#xA0;ng/mL at 15&#xA0;min]. She was diagnosed as ACTH, TSH, LH and FSH insufficiency as well as central diabetes insipidus by additional loading tests. Osteoporosis was diagnosed by BMD [T-score of the lumbar spine and the femoral neck were &#x2212;2.0 SD and &#x2212;2.5 SD, respectively].</p>
      <p>The therapeutic course was shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>. The levels of liver enzymes did not change for three months after the replacement of hydrocortisone (5&#xA0;mg/day) and oral desmopressin (30&#xA0;&#x3BC;g/day). When 60&#xA0;mg anti-RANKL antibody was subcutaneously injected to treat the osteoporosis every six months, the levels of her liver enzymes were rapidly decreased after the first and second administration (levels of ALT and &#x3B3;GTP at nine months later were 60 U/L and 117 U/L, respectively). Then, GH replacement therapy (0.033&#xA0;mg/kg/week after 0.017&#xA0;mg/kg/week for two month) and levothyroxine (25&#xA0;&#x3BC;g/day) were initiated, however, the levels of liver enzymes were increased and were not changed despite improvement of IGF-1 concentrations (ALT and &#x3B3;GTP were 114 U/L and 157 U/L at around 12&#xA0;months after the beginning of the treatment, respectively). However, the levels of liver enzymes were decreased again after third administration of anti-RANKL antibody (ALT and &#x3B3;GTP were 72 U/L and 99 U/L at 16&#xA0;months after the beginning of the treatment, respectively).<fig id="Fig2"><label>Fig. 2</label><caption><p>Changes in the liver enzymes, body weight and IGF-1 after the initiation of hormone replacement and anti-RANKL antibody. After the replacement of hydrocortisone 5&#xA0;mg/day and oral desmopressin 30&#xA0;&#x3BC;g/day, the liver enzymes were unchanged. Three months later anti-RANKL antibody 60&#xA0;mg was administered, and plasma levels of ALT and &#x3B3;GTP were decreased from 133 to 62 U/L and from 284 to 171 U/L, respectively. Reduction of liver enzymes was also confirmed after second and third administration of anti-RANKL antibody. GH and levothyroxin replacement were initiated between the second and the third administration of anti-RANKL antibody, and IGF-1 level was increased to normal range. However, the liver enzymes were not decreased by replacement with GH and levothyroxin. She gained 6.1&#xA0;kg of weight during the treatment period</p></caption><graphic xlink:href="12902_2016_148_Fig2_HTML" id="MO2"/></fig>
</p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>NASH is characterized by inflammation and fibrosis in addition to fat deposition within hepatocytes. Many pro-inflammatory cytokines including tumor necrosis factor-&#x3B1; (TNF-&#x3B1;) are involved in the progression of NASH [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. A recent study showed that hepatocyte-specific RANK knockout mice had significantly lower liver fat content compared with control mice concomitant with a decrease in production of inflammatory cytokines such as TNF-&#x3B1; from hepatocytes and kupffer cells [<xref ref-type="bibr" rid="CR13">13</xref>], indicating that RANKL-RANK signaling pathway potentially is associated with hepatitis. In our case, the amelioration of liver enzymes was associated with the administration of anti-RANKL antibody, suggesting that RANKL-RANK signaling pathway may be one of the potential pathogenesis for the development of NAFLD or NASH under the condition of panhypopituitarism including GH deficiency.</p>
      <p>Unlike previous cases [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>], GH replacement therapy was not clearly associated with liver dysfunction in this case. Sufficient dose of GH was given to her because her IGF-1 levels were within normal range for her age. Matsumoto et al. reported that improvement of liver dysfunction after GH replacement in GHD patients was observed at least within three months [<xref ref-type="bibr" rid="CR5">5</xref>], indicating that short duration of the GH replacement was not the reason for prolonged liver dysfunction in this case. In contrast to previous cases, GH was replaced under the administration of anti-RANKL antibody in this case. The finding that GH replacement after administration of anti-RANKL antibody was not effective suggested that mechanism of amelioration of hepatitis by GH replacement therapy may be identical with inhibition of RANK signaling for production of inflammatory cytokines in hepatocytes. This observation indicated that RANKL-RANK signaling may play a crucial role in progression of NAFLD or NASH in patients with panhypopituitarism including GH deficiency.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>Present case showed that administration of anti-RANKL antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a women patient with aGHD concomitant with NASH. The clinical course of the present case suggested that RANKL-RANK signaling may be a key pathological mechanism in development of NASH in patients with panhypopituitarism including GH deficiency. Agents to inhibit RANK-RANKL signaling in hepatocytes might be beneficial for treatment of NASH in these populations.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>aGHD</term>
          <def>
            <p>Adult growth hormone deficiency</p>
          </def>
        </def-item>
        <def-item>
          <term>BMD</term>
          <def>
            <p>Bone mineral density</p>
          </def>
        </def-item>
        <def-item>
          <term>GHD</term>
          <def>
            <p>Growth hormone deficiency</p>
          </def>
        </def-item>
        <def-item>
          <term>GHRP-2</term>
          <def>
            <p>Growth hormone releasing peptide-2</p>
          </def>
        </def-item>
        <def-item>
          <term>IGF-1</term>
          <def>
            <p>Insulin-like growth factor-1</p>
          </def>
        </def-item>
        <def-item>
          <term>NAFLD</term>
          <def>
            <p>Non-alcoholic fatty liver disease</p>
          </def>
        </def-item>
        <def-item>
          <term>NASH</term>
          <def>
            <p>Non-alcoholic steatohepatitis</p>
          </def>
        </def-item>
        <def-item>
          <term>RANK</term>
          <def>
            <p>Receptor activator of nuclear factor-kappa B</p>
          </def>
        </def-item>
        <def-item>
          <term>RANKL</term>
          <def>
            <p>Receptor activator of nuclear factor-kappa B ligand</p>
          </def>
        </def-item>
        <def-item>
          <term>T2DM</term>
          <def>
            <p>Type 2 diabetes mellitus</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Acknowledgements</title>
      <p>None.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>None.</p>
      </sec>
      <sec id="FPar2">
        <title>Availability of data and materials</title>
        <p>All data contained within the article.</p>
      </sec>
      <sec id="FPar3">
        <title>Authors&#x2019; contributions</title>
        <p>AT and MY interpreted the data and drafted the manuscript. TS revised the manuscript. AT, MN and MY participated in the endocrinological treatment, and collected the data. All authors read and approved the final manuscript.</p>
      </sec>
      <sec id="FPar4">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar5">
        <title>Consent for publication</title>
        <p>Written informed consent was obtained from the patient of this case report.</p>
      </sec>
      <sec id="FPar6">
        <title>Ethics approval and consent to participate</title>
        <p>Not applicable.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Serag</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular carcinoma</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>365</volume>
          <issue>12</issue>
          <fpage>1118</fpage>
          <lpage>1127</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra1001683</pub-id>
          <pub-id pub-id-type="pmid">21992124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kanzaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Seino</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Effect of growth hormone on fatty liver in panhypopituitarism</article-title>
          <source>Arch Dis Child</source>
          <year>1997</year>
          <volume>76</volume>
          <issue>6</issue>
          <fpage>537</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.76.6.537</pub-id>
          <pub-id pub-id-type="pmid">9245856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ejima</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Eguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakao</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency</article-title>
          <source>Gut</source>
          <year>2003</year>
          <volume>52</volume>
          <issue>6</issue>
          <fpage>914</fpage>
          <pub-id pub-id-type="doi">10.1136/gut.52.6.914</pub-id>
          <pub-id pub-id-type="pmid">12740357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fukuoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takeno</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Imanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nishizawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency</article-title>
          <source>Gastroenterology</source>
          <year>2007</year>
          <volume>132</volume>
          <issue>3</issue>
          <fpage>938</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2006.12.024</pub-id>
          <pub-id pub-id-type="pmid">17324404</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsumoto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fukuoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iguchi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nishizawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bando</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency</article-title>
          <source>Growth Hormon IGF Res : official journal of the Growth Hormone Research Society and the International IGF Research Society</source>
          <year>2014</year>
          <volume>24</volume>
          <issue>5</issue>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ghir.2014.07.002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishizawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iguchi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Murawaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fukuoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kaji</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy</article-title>
          <source>Eur J Endocrinol/European Federation of Endocrine Societies</source>
          <year>2012</year>
          <volume>167</volume>
          <issue>1</issue>
          <fpage>67</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-12-0252</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yasuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kinosaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mochizuki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tomoyasu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1998</year>
          <volume>95</volume>
          <issue>7</issue>
          <fpage>3597</fpage>
          <lpage>3602</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.95.7.3597</pub-id>
          <pub-id pub-id-type="pmid">9520411</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cummings</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>San Martin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McClung</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Siris</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Eastell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Delmas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zoog</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Austin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Denosumab for prevention of fractures in postmenopausal women with osteoporosis</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>361</volume>
          <issue>8</issue>
          <fpage>756</fpage>
          <lpage>765</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0809493</pub-id>
          <pub-id pub-id-type="pmid">19671655</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boonen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Man</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Lippuner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Torring</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Farrerons</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Franchimont</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <issue>6</issue>
          <fpage>1727</fpage>
          <lpage>1736</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-2784</pub-id>
          <pub-id pub-id-type="pmid">21411557</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Copaci</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Micu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Voiculescu</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The role of cytokines in non-alcoholic steatohepatitis. A review</article-title>
          <source>J Gastrointestin liver Dis : JGLD</source>
          <year>2006</year>
          <volume>15</volume>
          <issue>4</issue>
          <fpage>363</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="pmid">17205149</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koteish</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mae Diehl</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Animal models of steatohepatitis</article-title>
          <source>Best Pract Res Clin Gastroenterol</source>
          <year>2002</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>679</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1053/bega.2002.0332</pub-id>
          <pub-id pub-id-type="pmid">12406439</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buzzetti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pinzani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsochatzis</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)</article-title>
          <source>Metab Clin Exp</source>
          <year>2016</year>
          <volume>65</volume>
          <issue>8</issue>
          <fpage>1038</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/j.metabol.2015.12.012</pub-id>
          <pub-id pub-id-type="pmid">26823198</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiechl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wittmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Giaccari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Knoflach</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Willeit</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bozec</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moschen</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Muscogiuri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sorice</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Kireva</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus</article-title>
          <source>Nat Med</source>
          <year>2013</year>
          <volume>19</volume>
          <issue>3</issue>
          <fpage>358</fpage>
          <lpage>363</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3084</pub-id>
          <pub-id pub-id-type="pmid">23396210</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
